The Aim of the Study is to Decipher the Alterations in Signalling Pathways of Skeletal Muscle Stem Cells (Satellite Cells (SCs)) in Individuals With COPD, as Well as to Examine the Effect of Exercise Training on SCs. (SCOOP)
Study of Satellite Cells in COPD-associated sarcOPenia (Satellite Cells in COPD Sarcopenia) : Exploratory Cohort Study for Translational Research
The aim of the study is to decipher the alterations in signalling pathways of skeletal muscle stem cells (satellite cells (SCs)) in individuals with COPD, as well as to examine the effect of exercise training on SCs. To this end, the team will perform an exhaustive evaluation of lung and muscle function, including exercise capacity, as well as muscle biopsies, before and after a 2-months rehabilitation program. This study should provide new therapeutic avenues for COPD-associated sarcopenia.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Chronic obstructive pulmonary disease (COPD) is now to be considered as a multimorbid disease, originating from a combination of several risk factors (respiratory events in childhood, exposure to inhaled particles, physical inactivity, etc.), and simultaneously affecting several organs. This multi-organ impairment is likely to arise from common biological processes such as systemic inflammation or repair failure. Studying these processes in an organ that is easily accessible to biopsy, such as skeletal muscle, can help in the overall management of COPD. Skeletal muscle wasting (or sarcopenia: loss of muscle mass and force) is also a major comorbidity in COPD, both frequent and associated to increased mortality. Muscle stem cells (satellite cells) are responsible for repairing skeletal muscle tissue after injury, notably after micro-lesions induced by exercise. However, they have been scarcely studied in COPD. In the present project, the team proposes to study repair abnormalities in skeletal muscle tissue by comparing the signalling pathways activated in satellite cells of patients with COPD, before and after a respiratory rehabilitation programme (20 sessions over 8 to 12 weeks). The team will carry out an exhaustive respiratory and muscular assessment at inclusion and at the end of the 20 sessions, evaluating in particular respiratory function and exercise capacity (Pulmonary Function Tests, cardio-pulmonary exercise testing with VO2max measurement, 6-minute walking test, handgrip test) as well as a quadricipital muscle biopsy with the modified Bergström's technique. Muscle biopsies will be used to culture satellite cells and assess their regenerative capacity in vitro, as well as to analyse dysregulated signalling pathways at the transcriptomic level with single-cell RNAsequencing. The results should help to identify new therapeutic avenues for the comprehensive management of multimorbid COPD.
Studientyp
Einschreibung (Geschätzt)
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
- Name: Pauline HENROT, MD
- Telefonnummer: +33(0)5 57 65 65 13
- E-Mail: pauline.henrot@chu-bordeaux.fr
Studienorte
-
-
-
Créteil, Frankreich, 94000
- Hôpital Henri-Mondor
-
Kontakt:
- Laurent BOYER, MD, PhD
- Telefonnummer: +33(0)1 49 81 26 81
- E-Mail: laurent.boyer@aphp.fr
-
Paris, Frankreich, 75013
- Hôpital Pitié-Salpêtrière
-
Kontakt:
- Romy RATSIHORIMANANA, MD
- Telefonnummer: +33(0)1 42 16 77 99
- E-Mail: romy.ratsihorimanana@aphp.fr
-
Pessac, Frankreich, 33400
- CHU de Bordeaux
-
Kontakt:
- Pauline HENROT, MD
- Telefonnummer: +33(0)5 57 65 65 13
- E-Mail: pauline.henrot@chu-bordeaux.fr
-
Hauptermittler:
- Pauline HENROT, MD
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Adult male or female (age 18 years or older);
- Having a diagnosis of COPD according to the GOLD (Global Initiative for Lung Disease) 2024 criteria, i.e. a non-reversible bronchial obstruction in spirometry with a post-bronchodilator Tiffeneau coefficient < 70%;
- Less than or equal to 75 years of age;
- Must benefit from exercise retraining sessions or respiratory rehabilitation as part of the management of COPD;
- Person affiliated to or beneficiary of a social security scheme (excluding State Medical Aid (AME));
- Free, informed and written consent signed by the participant or by a third party (in the event of the participant's physical disability) and the investigator (no later than the day of inclusion and before any review required by the research).
Exclusion Criteria:
- Moderate or severe acute exacerbation of COPD, or acute intercurrent condition (e.g., infection) that has been ongoing or resolved for less than 4 weeks;
- Systemic corticosteroid therapy in progress or stopped for less than 4 weeks;
- Contraindication to respiratory rehabilitation: tight aortic stenosis, unstable heart failure, active thromboembolic disease, ventricular aneurysm, uncontrolled arrhythmias;
- Contraindication to muscle biopsy: acquired or innate haemostasis disorders, anticoagulant treatment or double anti-platelet aggregation; contraindication to lidocaine: known hypersensitivity, patients with recurrent porphyrias;
- Presence of a concomitant muscle pathology, innate (e.g., genetic myopathy) or acquired (e.g., myositis, progressive cancer);
- Pregnant or breastfeeding woman;
- Patient under guardianship or curatorship;
- Refusal to participate in the study.
Exclusion criteria:
- Hemostasis disorders.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Men or women (adults) with a diagnosis of COPD according to GOLD criteria
|
Patients will undergo an exhaustive respiratory and muscular check-up (including quadridipital muscle biopsies) at inclusion and at the end of the respiratory rehabilitation program (a minimum of 20 sessions at a rate of 2 to 3 sessions per week for 8 to 12 weeks). |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Change in single-cell gene expression profile of muscle satellite cells after pulmonary rehabilitation
Zeitfenster: Day 1 (baseline, Visit 1) and Week 10 (± 2 weeks; Visit 2)
|
Intra-individual comparison of messenger RNA (mRNA) expression in muscle satellite cells isolated from quadriceps muscle biopsies collected before and after the pulmonary rehabilitation programme. Satellite cells will be isolated and analysed using single-cell and single-nucleus RNA sequencing. The outcome is the change in the gene-expression profile, including differentially expressed genes and associated molecular signalling pathways, between baseline and the end of rehabilitation. |
Day 1 (baseline, Visit 1) and Week 10 (± 2 weeks; Visit 2)
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Pauline HENROT, University Hospital, Bordeaux
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Neurologische Manifestationen
- Erkrankungen des Nervensystems
- Neuromuskuläre Manifestationen
- Pathologische Prozesse
- Pathologische Zustände, Anatomisch
- Chronische Erkrankung
- Krankheitsattribute
- Erkrankungen der Atemwege
- Lungenkrankheit
- Lungenerkrankungen, obstruktive
- Atrophie
- Pathologische Zustände, Anzeichen und Symptome
- Anzeichen und Symptome
- Lungenerkrankung, chronisch obstruktiv
- Sarkopenie
- Muskelatrophie
- Motorik
- Bewegung
- Phänomen des Bewegungsapparates muskuloskelettal
- Muskuloskelettaler und neuronales physiologisches Phänomen
- Übung
Andere Studien-ID-Nummern
- CHUBX 2026/005
- 2026-A00609-42 (Andere Kennung: French National Agency for Safety of Medicines and Health Products)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
The data is available from Dr HENROT . An email can be sent to her so that she can contact the data manager and owner, the Bordeaux University Hospital. The data can be made available after contractual agreement.
Art der unterstützenden IPD-Freigabeinformationen
- STUDIENPROTOKOLL
- ICF
- CSR
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .